Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Human Umbilical Cord Mesenchymal Stem Cells for Decompensated Hepatitis B Cirrhosis
NCT03826433Phase 1Recruiting
- Sponsor
- Sclnow Biotechnology Co., Ltd.
- Start
- Oct 2018
- Primary completion
- Dec 2026
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of human umbilical cord mesenchymal stem cells (2 arms), sponsored by Sclnow Biotechnology Co., Ltd. Primary endpoint: Model for End-Stage Liver Disease score at 12 months. Started Oct 2018; status: recruiting.
02
Drugs
human umbilical cord mesenchymal stem cells
Beyond the preview
Go deeper on NCT03826433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03826433.